Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neural TherapeuticsNURLF EV-to-OCF is 0.00 as of Sep. 17, 2026. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Neural Therapeutics ranks better than 57.33% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Neural Therapeutics's Enterprise Value is $0.00 Mil.
Neural Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.29 Mil. Therefore, Neural Therapeutics's EV-to-OCF for today is 0.00.
The historical rank and industry rank for Neural Therapeutics's EV-to-OCF or its related term are showing as below:
NURLF's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.335 * Ranked among companies with meaningful EV-to-OCF only.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neural Therapeutics's PE Ratio (TTM) for today is calculated as:
Neural Therapeutics's share price for today is $0.0022.
Neural Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Neural Therapeutics EV-to-OCF Related Terms
Neural Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Neural Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neural Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neural Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neural Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Neural Therapeutics's EV-to-OCF falls into.
Neural Therapeutics's current Enterprise Value is $0.00 Mil.
Neural Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neural Therapeutics (NURLF) has a EV-to-OCF of 0.00 as of Sep. 17, 2026. According to the industry distribution chart, Neural Therapeutics ranks #600 out of 1406 companies in the Biotechnology industry, placing it in the top 42.7%.
Is Neural Therapeutics' EV-to-OCF too high?
Neural Therapeutics' current EV-to-OCF is 0.00. Based on the distribution chart, Neural Therapeutics ranks #600 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint.
How does Neural Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #600 out of 1406 companies for EV-to-OCF. This puts Neural Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Neural Therapeutics's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current EV-to-OCF is 0.00 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NURLF has been successfully added to your 
